<PAGE>
Rule 497(d)
File No. 333-32332
Supplement dated March 30, 2000 to the Prospectus dated March 22, 2000
Nuveen Unit
Trusts, Series 85
Nuveen Biotechnology & Genome Five-Year Sector Portfolio, March 2000
Notwithstanding anything to the contrary in the Prospectus, Unitholders who
acquire Units of the Nuveen Biotechnology & Genome Five-Year Sector Portfolio,
March 2000 Series which, as a result of a reduction in the aggregate underlying
value of the Securities, are not subject to an initial sales charge will be
subject to the maximum remaining deferred sales charge (initial $.35 per Unit).
In such case the maximum sales charge may exceed 4.5% of the Public Offering
Price per Unit, but in no event will the maximum sales charge exceed 5.50% of
the Public Offering Price per Unit.
